HOME >> MEDICINE >> NEWS
FDA approves Pfizer's Lyrica for the treatment of the two most common forms of neuropathic pain

NEW YORK, December 31, 2004 - Pfizer Inc said today that it has received approval from the U.S. Food and Drug Administration (FDA) to market LyricaTM (pregabalin capsules) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). Lyrica is the first FDA-approved treatment for both of these neuropathic pain states, which are distinctly different from arthritis or musculoskeletal pain.

Developed by Pfizer, Lyrica has a newly defined mechanism of action. Lyrica will be available to physicians and patients in the near future.

"Lyrica is an important new therapy for millions of people suffering from the two most common neuropathic pain conditions as it provides rapid and sustained pain relief," said Dr. Joseph Feczko, president of Worldwide Development at Pfizer. "Lyrica also represents a major achievement in Pfizer's research program and confirms our leadership in bringing life-changing medicines to patients."

Neuropathic pain, one of the most debilitating forms of pain, is caused by nerve damage that can result from underlying conditions, such as diabetes or shingles. Nearly half of the 18 million Americans with diabetes will develop some form of diabetic neuropathy over the course of their disease and about one in six diabetes patients will experience painful diabetic neuropathy. The pain of DPN is often described as burning, tingling, sharp, stabbing, or pins and needles in the feet, legs, hands or arms.

PHN is a complication of shingles, a painful outbreak of rash or blisters on the skin caused by a reactivation of the same virus that causes chicken pox. Each year, about 150,000 Americans develop PHN, which is often characterized as constant stabbing, burning, or electric shock-like sensation.

The efficacy of Lyrica was established in six double-blind, placebo-controlled trials, three involving patients with DPN and three involving patients with
'"/>

Contact: Rebecca Hamm
212-733-8811
Burson-Marsteller
7-Jan-2005


Page: 1 2

Related medicine news :

1. FDA approves Enablex for treatment of overactive bladder
2. FDA approves Fosrenol(R) in end-stage renal disease (ESRD) patients
3. FDA approves Adderall XR (R) to treat ADHD in adults
4. FDA approves EPZICOM
5. FDA approves new labelling for Seroquel in bioplar mania
6. FDA approves Enbrel to treat psoriasis
7. FDA approves Climara Pro to treat menopause symptoms
8. FDA approves new approach to schizophrenia treatment
9. FDA approves new HIV protease inhibitor, Lexiva (TM)
10. FDA approves Wellbutrin XL(TM)
11. FDA approves Baxters ADVATE for the treatment of hemophilia A

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/6/2016)... Grants Pass, OR (PRWEB) , ... May 06, 2016 , ... ... the eyes. In other seasons, when the weather is too cold, dry or hot, ... weather, the eyes can actually absorb moisture from the surrounding air. There’s only one ...
(Date:5/6/2016)... ... ... From the Speaker Podium to the Exhibit Floor at Booth#514, Worldwide Leading Contact Center ... at SpeechTek 2016 Event, taking place May 23-25 at the Omni Shoreham in Washington ... “5 Customer Engagement Strategies to improve Customer Satisfaction in your Contact Center” on May ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... to Sleepopolis.com . , Since launching in September, 2014 Sleepopolis has resided ... testing areas, which now include pillows, sheets, mattress toppers, bed frames, and more. ...
(Date:5/6/2016)... NJ (PRWEB) , ... May 06, 2016 , ... ... December 2013 arrival of Sovaldi, which made headlines mostly for its cost despite ... then, policy and moral questions surrounding the drug—part of a class called direct-acting ...
(Date:5/6/2016)... ... May 06, 2016 , ... Kenneth Cochran, ... of Cardiovascular Institute of the South announced today that Dr. Robert Menuet, Interventional ... of an Intravascular Ultrasound Guided Coronary Atherectomy. , This procedure involves ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Actinic Keratosis Market and ... their offering.       (Logo: ... Market and Competitive Landscape Highlights 2016, provides ... Actinic Keratosis epidemiology, Actinic Keratosis market valuations ...
(Date:5/3/2016)... PUNE, India , May 4, 2016 /PRNewswire/ ... report spreads across 154 pages, profiling 09 key ... It is a professional and in-depth study on ... providing a basic overview of the industry including ... Insulin Needles market analysis is provided for the ...
(Date:5/3/2016)... , May 4, 2016 Research ... "Global Cancer Stem Cell Therapy Market Outlook 2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has improved significantly ... expected to be developed in coming years. Many cancer ... Cancer stem cell therapies are also expected to be ...
Breaking Medicine Technology:
Cached News: